Placental-derived mesenchymal stem cells for treatment of multiple sclerosis

Placental mesenchymal stem cells (MSCs) were injected to chronic experimental autoimmune encephalomyelitis (EAE) mice, 5 or 14 days post-EAE induction. Disease severity scores were significantly reduced and animal survival was prolonged, but without delay in symptom onset. In addition, an anti-inflammatory effect was demonstrated in the treatment group.